Aflibercept (VEGF Trap) is a unique fusion protein that binds all forms of Vascular Endothelial Growth Factor-A (called VEGF-A). VEGF-A is required for the growth of new blood vessels that are needed for tumors to grow and is a potent regulator of vascular permeability and leakage. In addition, aflibercept binds Placental Growth Factor (PLGF), which has also been implicated in tumor angiogenesis.

Regeneron and the sanofi-aventis Group, an industry leader in the field of oncology, have a global collaboration to develop and commercialize aflibercept.

Aflibercept Clinical Development

Regeneron and the sanofi-aventis Group have initiated four phase 3 trials evaluating aflibercept in combination with standard chemotherapy regimens in patients with prostate cancer, Non-Small Cell Lung Cancer (NSCLC), colorectal cancer and pancreatic cancer. Phase 2 clinical trials are ongoing in patients with Advanced Ovarian Cancer (AOC), NSCLC and AOC patients with symptomatic malignant ascites. In two phase 1 dose escalation studies, aflibercept was generally well-tolerated at all doses studied. Efficacy analysis showed evidence of tumor size reduction and prolonged stable disease in some patients after aflibercept treatment as a single agent.

This section discusses Regeneron's pipeline of drug candidates currently undergoing clinical testing in a variety of diseases. These drug candidates have not been approved by the United States Food and Drug Administration for the indications described in this section.